Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

Detailed summary

Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response…

NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 ICOTYDE met the primary endpoint, with 58% of patients achieving an American College…

Psoriatic arthritis is a chronic, immune-mediated inflammatory disease that can affect both the joints and skin.3,4 Nearly 30 percent of people with plaque psoriasis also develop psoriatic arthritis.5,6 It can cause pain, stiffness and swelling in and around the joints, along with the skin lesions associated with plaque psoriasis.7 Because inflammation can lead to progressive disease, there remains a need for…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.